Skip to main content
AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.520
+0.070 (2.03%)
At close: Mar 9, 2026, 4:00 PM EDT
3.530
+0.010 (0.28%)
After-hours: Mar 9, 2026, 4:36 PM EDT

AbCellera Biologics Revenue

In the year 2025, AbCellera Biologics had annual revenue of $75.13M with 160.56% growth. AbCellera Biologics had revenue of $44.85M in the quarter ending December 31, 2025, with 788.18% growth.

Revenue (ttm)
$75.13M
Revenue Growth
+160.56%
P/S Ratio
14.00
Revenue / Employee
$126,054
Employees
596
Market Cap
1.07B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202575.13M46.30M160.56%
Dec 31, 202428.83M-9.19M-24.17%
Dec 31, 202338.03M-447.40M-92.17%
Dec 31, 2022485.42M110.22M29.38%
Dec 31, 2021375.20M142.05M60.92%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Pharming Group 362.27M
Xeris Biopharma Holdings 291.85M
Geron 183.88M
UroGen Pharma 109.79M
Inventiva 19.93M
Aktis Oncology 5.56M
Inhibrx Biosciences 1.40M
Compass Therapeutics 850.00K
Revenue Rankings

ABCL News

More News